ACTINIUM PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 4.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-07
- ACTINIUM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 87.00K shares, a 80.74% decline year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 5.01M shares, a 1630869.71% increase year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-12-31 was 451.68K shares, a 46.28% increase year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-09-30 was 307.00 shares.
- ACTINIUM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 5.10M shares, a 1028.10% increase from fiscal 2024.
- ACTINIUM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 452.00K shares, a 46.28% increase from fiscal 2023.
- ACTINIUM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 309.00K shares, a 514900.00% increase from fiscal 2022.
- ACTINIUM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 60.00 shares, a 81.98% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.00K shares 10-Q · filed 2026-08-07 | |||
| 2025-12-31 | 87.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 5.09M shares derived: sum of 2 quarters · filed 2026-03-30 | 5.10M shares 10-K · filed 2026-03-30 | |
| 2025-09-30 | 5.01M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 5.01M shares 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | 4.92K shares 10-Q · filed 2025-08-08 | |||
| 2024-12-31 | 451.68K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 451.98K shares derived: sum of 2 quarters · filed 2026-03-30 | 451.99K shares derived: sum of 3 quarters · filed 2026-03-30 | 452.00K shares 10-K · filed 2026-03-30 |
| 2024-09-30 | 307.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 309.00 shares derived: sum of 2 quarters · filed 2024-11-14 | 323.00 shares 10-Q · filed 2024-11-14 | 309.11K shares derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | 2.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | 16.00 shares 10-Q · filed 2024-08-05 | 308.80K shares derived: sum of 3 quarters · filed 2025-03-31 | 224.02K shares derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | 14.00 shares 10-Q · filed 2024-04-26 | 308.80K shares derived: sum of 2 quarters · filed 2025-03-31 | 224.01K shares derived: sum of 3 quarters · filed 2025-03-31 | 227.01K shares derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | 308.79K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 224.00K shares derived: sum of 2 quarters · filed 2025-03-31 | 227.00K shares derived: sum of 3 quarters · filed 2025-03-31 | 309.00K shares 10-K · filed 2025-03-31 |
| 2023-09-30 | -84.79K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -81.79K shares derived: sum of 2 quarters · filed 2023-11-02 | 214.00 shares 10-Q · filed 2023-11-02 | 219.00 shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | 3.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 85.00K shares 10-Q · filed 2023-08-14 | 85.00K shares derived: sum of 3 quarters · filed 2023-08-14 | 85.01K shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 82.00K shares 10-Q · filed 2023-05-15 | 82.00K shares derived: sum of 2 quarters · filed 2023-05-15 | 82.01K shares derived: sum of 3 quarters · filed 2023-05-15 | |
| 2022-12-31 | 5.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 9.00 shares derived: sum of 2 quarters · filed 2023-03-31 | 60.00 shares 10-K · filed 2023-03-31 | |
| 2022-09-30 | 4.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 55.00 shares 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | 51.00 shares 10-Q · filed 2022-08-12 | |||
| 2021-12-31 | 333.00 shares 10-K · filed 2023-03-31 | |||
| 2021-03-31 | 22.00K shares 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |